

Gilead Abstracts EACS 2021

HIV Treatment (B/F/TAF)

Study #/Topic	Disposition	Presenter	Title	Presentation Date and Time
HIV Treatment (B/F/TAF)				
GS-EU-380-4472 (BICSTaR)	Poster PE2/57	J Mallolas	Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV (PLWH): 12-month (12M) effectiveness, persistence, and safety in a multi-country cohort study	E-Poster
GS-EU-380-4472 (BICSTaR)	Poster PE2/50	J Brunetta	Patient-reported outcome (PRO) measures at 12 months (12M) in a real-world cohort of people living with HIV (PLWH) with a high prevalence of comorbidities receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Europe, Canada, and Israel	E-Poster
GS-US-380-1489 GS-US-380-1490	Poster PE2/68	A Pozniak	Outcomes 48 weeks after switching from DTG/ABC/3TC or DTG+F/TAF to B/F/TAF	E-Poster
GS-US-380-1878	Poster PE1/19	Kristen Andreatta	Long-term efficacy of bictegravir/emtricitabine/tenofovir alafenamide after switch from boosted protease inhibitor-based regimens including in those with preexisting resistance and viral blips	E-Poster
GS-US-380-1878 GS-US-380-1844 GS-US-380-4030 GS-US-380-4449 GS-US-380-4580	Poster PE1/6	Kristen Andreatta	Prevalence and risk factors of preexisting tams in clinical trial participants and sustained viral suppression after switching to bictegravir/emtricitabine/tenofovir alafenamide	E-Poster
<i>In Vitro</i> Analysis	Poster PE2/68	Rimas Acosta	In vitro forgiveness of oral and long-acting INSTI-containing regimens at drug concentrations simulating variable adherence	E-Poster
Persistence (MAR)	Poster PE7/28	Dylan Mezzio	Persistence for guideline-recommended HIV treatment: comparison among US medicaid beneficiaries newly initiating treatment with single- versus multiple-tablet regimens	E-Poster

HIV Prevention

Study #/Topic	Disposition	Presenter	Title	Presentation Date and Time
HIV Prevention				
UK modeling study (GV&A and UK HIV)	Poster BPD2/1	M Chaponda	Investigating Zero Transmission of HIV in the MSM Population: A UK Modelling Study	Thu, Oct 28th 12:00-12:06 GMT (Best Posters 2 - Social Sciences & Prevention)
<i>In silico</i> simulation	Poster PE6/19	E Grebe	Context-specific performance of recency assays in South Africa and Uganda: an <i>in silico</i> simulation approach	E-Poster

LEN (Long-Acting Capsid Inhibitor)

Study #/Topic	Disposition	Presenter	Title	Presentation Date and Time
LEN (Long-Acting Capsid Inhibitor)				
GS-US-200-4625 (CAPELLA)	Oral OS1/1	Nicolas Margot	Resistance analysis of long-acting lenacapavir in highly treatment-experienced people with HIV after 26 weeks of treatment	Thu, Oct 28th 15:00-15:10 GMT (Oral Abstract Session 2 - Current issues in ART)
GS-US-200-4625 (CAPELLA)	Poster PE2/69	HJ Stellbrink	Subgroups efficacy analyses of long-acting subcutaneous lenacapavir in phase 2/3 in heavily treatment-experienced people with HIV	E-Poster

COVID-19 (Remdesivir)

Study #/Topic	Disposition	Presenter	Title	Presentation Date and Time
COVID-19 (Remdesivir)				
SARS-COV-2	Poster PE1/2	Joy Feng	NRTIs tenofovir, TAF, TDF, and FTC are inactive against SARS-CoV-2	E-Poster

HIV Treatment (Inflammation, STR vs MTR, PROs, Assessing Comorbidities)

Study #/Topic	Disposition	Presenter	Title	Presentation Date and Time
HIV Treatment (Inflammation, STR vs MTR, PROs, Assessing Comorbidities)				
Inflammation	Poster PE2/34	S Serrano Villar	The potential clinical impact of the observed differences in IL-6, a marker of inflammation, associated with some antiretroviral regimens	E-Poster
Real-world evidence, non-interventional (MAR)	Poster PE2/33	B Chastek	Characteristics, treatment patterns, and viral load for treatment-experienced people living with HIV and switching to an MTR or STR ARV after 2018	E-Poster
GS-DE-292-1912	Poster PE2/45	L Williams	Analyses of patient reported outcomes for appropriately tailoring to needs of HIV-1 patient focus groups	E-Poster
Monitoring comorbidities	Poster PE5/34	Breda Patterson	Guidelines for the assessment and monitoring of comorbidities in people living with human immunodeficiency virus (PLHIV): a systematic review	E-Poster

HIV Cure

Study #/Topic	Disposition	Presenter	Title	Presentation Date and Time
HIV Cure				
Vesatolimod (VES, formerly GS-9620; TLR-7 Agonist)				
Immune biomarkers/ modeling study	Poster PE2/1	E Vendrame	Mathematical modeling identifies predictive immune biomarkers of HIV post-treatment controllers	E-Poster

Investigator-Sponsored Research and Collaborative Studies: EACS 2021

HIV Treatment (B/F/TAF)

Study #/Topic	Disposition	Presenter	Title	Presentation Date and Time
HIV Treatment (B/F/TAF)				
IN-AU-380-4654	Poster PE2/32	J Carson	Tolerability and antiviral activity of bicitegravir/tenofovir alafenamide/emtricitabine (Biktarvy) treatment switch in patients aged 55 years or older with HIV: the BIO study	E-Poster
IN-IT-380-4666	Poster PE2/40	A Vergori	Impact of switch from EFV/F/TDF to B/F/TAF on psychiatric symptoms and neurocognition	E-Poster
IN-IT-380-4666 (EBONY)	Poster PE2/47	S Cicalini	Efficacy and safety of switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bicitegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically-suppressed HIV patients (EBONY study)	E-Poster
CO-FR-380-5442 (SOLUBIC)	Poster PE2/76	L Hocqueloux	Bioavailability of solid vs.dissolved vs.crushed formulations of bicitegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) in healthy volunteers: the SOLUBIC study	E-Poster
B/F/TAF (Rapid Initiation)				
IN-IT-380-5660 (RAINBOW)	Poster PE2/27	M Camici	Feasibility, efficacy and safety of a rapid antiretroviral therapy start based on B/F/TAF in advanced HIV disease	E-Poster
IN-FR-380-4664 (FAST)	Poster PE2/7	A Bachelard	Efficacy and safety of using tenofovir alafenamide/emtricitabine/bicitegravir (TAF/FTC/ BIC) in a test and treat model: the FAST Study	E-Poster
CO-US-380-4644	Poster PE2/3	A Zuppelli	Patient reported and clinical outcomes of rapid start antiretroviral therapy with BFTAF	E-Poster

Weight/BMI

Study #/Topic	Disposition	Presenter	Title	Presentation Date and Time
Weight/BMI				
CO-EU-311-4042 (ADVANCE)	Poster PE2/64	K McCann	Week 144 body composition results from the ADVANCE trial	E-poster
CO-DE-985-5951	Poster PE3/7	L Mavarani	No difference in changes of the body mass index categories over 5 years in people living with HIV and the general population from the German Ruhr-area	E-poster

Bone/Renal

Study #/Topic	Disposition	Presenter	Title	Presentation Date and Time
Bone/Renal				
CO-EU-311-4042 (ADVANCE)	Poster PE2/62	Venter	Week 192 bone and renal markers from the ADVANCE trial	E-poster
IN-ES-380-5312	Poster PE3/52	ES Robert Güerri-Fernández	Changes in bone quality after switching from a TDF to a TAF based ART: a pilot randomized study	E-poster
IN-ES-380-5312	Poster PE3/54	ES Robert Güerri-Fernández	Long-term non-progression of HIV infection impacts negatively in bone quality	E-poster

Weight/BMI

Study #/Topic	Disposition	Presenter	Title	Presentation Date and Time
Cardiovascular				
IN-DK-120-4319 (COCOMO)	Poster PE3/11	M Suarez-Zdunek	High incidence of subclinical peripheral artery disease in people living with HIV: a 2-year follow-up study	E-Poster
CO-EU-311-4339 (RESPOND)	Poster BPD1/3	NJ Jaschinski	Recent abacavir use and incident cardiovascular disease in contemporary treated people living with hiv (PLWH) within the RESPOND cohort consortium	E-Poster/Best Poster Thu, Oct 28th 12:12-12:18 GMT <i>(Best Posters 1 - ART & Resistance)</i>

Bone/Renal

Study #/Topic	Disposition	Presenter	Title	Presentation Date and Time
HIV Treatment				
IN-ES-380-5312 (TARANIS)	Poster PE2/8	JL Meynard	Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) and rilpivirine/emtricitabine/tenofovir alafenamide (R/F/TAF) in treatment-naïve and treatment-experienced people living with HIV (PLWH) - 24-month results of the French TARANIS cohort	E-Poster
IN-ES-380-5312	Poster PE2/21	J Olalla	Use of EVG/COBI/FTC/TAF in HIV-1 naïve patients with severe immune suppression	E-Poster
IN-ES-380-5312	Poster PE2/22	J Olalla	EVG/COBI/FTC/TAF in HIV-1 naïve patients with severe immune suppression: evolution of weight and lipids	E-Poster

Other Comorbidities

Study #/Topic	Disposition	Presenter	Title	Presentation Date and Time
Other Comorbidities				
IN-DK-120-4319	Oral OS2/2	RF Thudium	Faster lung function decline in well-treated people living with HIV compared with uninfected controls: a longitudinal matched cohort study	Oral Fri, Oct 29 th 10:30-11:30 GMT <i>(Oral Abstract Session 3 - Comorbidities and Co-infections)</i>
IN-DK-120-4319	Poster PE3/8	J Hogh	Insulin resistance in PWH is associated with abdominal obesity and prior exposure to thymidine analogues and/or didanosine	E-Poster
CO-EU-311-4339 (RESPOND)	Poster PE3/33	DM Byonanebye	Incidence of hypertension in PLWH receiving INSTI versus other third drug ART regimens in the RESPOND cohort	E-Poster
IN-UK-164-0476 (POPPY)	Poster PE3/5	H Okhai	Onset of depressive symptoms over time amongst people living with HIV in the Pharmacokinetic and Clinical Observations in People Over Fifty (POPPY) study	E-Poster
IN-UK-164-0476 (POPPY)	Poster PE3/18	CA Sabin	Distinct groupings of people with HIV and pain associate differently with pain-related healthcare use and health-related quality-of-life (HRQoL): findings from the Pharmacokinetic and Clinical Observations in People Over Fifty (POPPY) study	E-Poster

HIV Co-Infection

Study #/Topic	Disposition	Presenter	Title	Presentation Date and Time
HIV Co-Infection				
IN-US-342-4275	Poster PE2/15	A Wong	Safety and efficacy of E/C/F/TAF switch followed by SOF/VEL antiviral HCV therapy followed by B/F/TAF simplification in HIV-HCV co-infected subjects receiving opioid agonist therapy with methadone or buprenorphine/Naloxone	E-Poster
CO-SW-985-5602	Poster PE3/67	L Begre	Persistent ALT elevation after 2 years of TDF/TAF-containing art among persons with HIV/HBV coinfection: a European multi-cohort collaboration (EURO-B)	E-Poster

Ending the Epidemic

Study #/Topic	Disposition	Presenter	Title	Presentation Date and Time
Ending the Epidemic				
IN-US-380-4636	Poster PE2/26	B Conway	A simplified approach to antiretroviral therapy among inner-city vulnerable residents with HIV infection: living up to the promise of 90-90-90	E-Poster

Remdesivir/COVID-19

Study #/Topic	Disposition	Presenter	Title	Presentation Date and Time
Remdesivir/COVID-19				
CO-UK-540-6111 (RWE; non-interventional)	Poster PE4/17	N Arber	Clinical outcomes of hospitalized COVID-19 patients by disease severity treated with remdesivir-NEAT ID 909REM study	E-poster
CO-UK-540-6111	Poster PE4/51	P Shah	Use of the NEWS2 score in clinical outcomes of hospitalized COVID-19 patients by disease severity treated with remdesivir	E-poster